Apollomics Inc - Warrants (01/04/2028

(Warrants)
NAS:APLMW (USA)   Warrants (01/04/2028)
$ 0.03 0 (0%) 08:09 PM EST
At Loss
P/B:
0.92
Market Cap:
$ 55.00K
Enterprise V:
$ 20.54M
Volume:
-
Avg Vol (2M):
39.43K
Volume:
-
At Loss
Avg Vol (2M):
39.43K

Business Description

Apollomics Inc
NAICS : 541714 SIC : 2834
ISIN : KYG0411D1152

Share Class Description:

APLMW: Warrants (01/04/2028)
Description
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
Name Current Vs Industry Vs History
Cash-To-Debt 8.11
Equity-to-Asset 0.74
Debt-to-Equity 0.11
Debt-to-EBITDA -0.03
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -39.2
3-Year EPS without NRI Growth Rate -40
3-Year FCF Growth Rate -3.2

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 55.56
9-Day RSI 52.91
14-Day RSI 51.57
6-1 Month Momentum % 100
12-1 Month Momentum % -70.29

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.95
Quick Ratio 2.95
Cash Ratio 2.79

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1
Shareholder Yield % -3.94